June 3 (Reuters) - Rapport Therapeutics is targeting a

valuation of about $637 million in its initial public offering

in the United States, as the biopharmaceutical company joins a

slew of firms looking to list their shares amid a rebound in the

capital markets.

The U.S. IPO market is staging a strong comeback after two

dismal years, thanks to a rally in the stock market and growing

optimism of a possible interest rate cut this year.

Rapport, backed by the venture capital arm of Johnson &

Johnson ( JNJ ), is seeking to raise up to $144 million by

selling 8 million shares priced between $16 and $18 apiece, it

said on Monday.

The Boston, Massachusetts-based company was formed in

February 2022 with founding support from Third Rock Ventures and

Johnson & Johnson Innovation-JJDC. It develops small molecule

medicines for patients suffering from central nervous system

disorders.

Rapport plans to list on the Nasdaq under the symbol "RAPP".

Goldman Sachs, Jefferies, TD Cowen and Stifel are the

underwriters for the offering.